PTC Therapeutics plans to request approval for its GT-AADC gene therapy, developed for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency, in the United States. Supported by positive data from clinical studies, the company expects to submit a biologics license application (BLA) with the U.S. Food and Drug Administration…
News
Recent Posts
- AAV2 gene therapy vector movement tracked over time in rat brain study
- We find that maybe it’s time for a smartwatch, after all
- NORD teams with AI company to create rare disease resources
- The first fight against AADC started on the floor with tummy time exercises
- Natera launches Zenith genomics to help speed rare disease diagnosis